세계의 고성능 바이오 재료 시장(2024-2028년)

The high performance biomaterials market is forecasted to grow by USD 8.48 bn during 2023-2028, accelerating at a CAGR of 11.29% during the forecast period. The report on the high performance biomaterials market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of musculoskeletal diseases and disorders, rising prevalence of dental diseases and related risk factors, and surging number of joint replacement and arthroplasty surgeries.

Technavio's high performance biomaterials market is segmented as below:

By Type

• Metallic
• Polymers
• Ceramic

By Application

• Orthopedics
• Dental
• Cardiovascular
• Plastic surgery
• Tissue engineering and others

By Geographical Landscape

• North America
• Europe
• APAC
• South America
• Middle East and Africa

This study identifies the development of high-performance biomaterials in tissue engineering as one of the prime reasons driving the high performance biomaterials market growth during the next few years. Also, progressive research on regenerative medicine and advancements in drug delivery systems will lead to sizable demand in the market.

The report on the high performance biomaterials market covers the following areas:

• High performance biomaterials market sizing
• High performance biomaterials market forecast
• High performance biomaterials market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading high performance biomaterials market vendors that include Advanced Medical Solutions Group Plc, Arctic Biomaterials Oy Ltd, BASF SE, Berkeley Advanced Biomaterials, CAM Bioceramics BV, CoorsTek Inc., Corbion nv, Covestro AG, Dentsply Sirona Inc., Evonik Industries AG, Himed LLC, Honeywell International Inc., Koninklijke DSM NV, Regenity Biosciences, RevBio Inc., Solesis, Stryker Corp., Victrex Plc, Zimmer Biomet Holdings Inc., and ZimVie Inc.. Also, the high performance biomaterials market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global high performance biomaterials market 2018 - 2022
• 4.2 Type Segment Analysis 2018 - 2022
• 4.3 Application Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Type

• 6.1 Market segments
• 6.2 Comparison by Type
• 6.3 Metallic - Market size and forecast 2023-2028
• 6.4 Polymers - Market size and forecast 2023-2028
• 6.5 Ceramic - Market size and forecast 2023-2028
• 6.6 Market opportunity by Type

7 Market Segmentation by Application

• 7.1 Market segments
• 7.2 Comparison by Application
• 7.3 Orthopedics - Market size and forecast 2023-2028
• 7.4 Dental - Market size and forecast 2023-2028
• 7.5 Cardiovascular - Market size and forecast 2023-2028
• 7.6 Plastic surgery - Market size and forecast 2023-2028
• 7.7 Tissue engineering and others - Market size and forecast 2023-2028
• 7.8 Market opportunity by Application

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 APAC - Market size and forecast 2023-2028
• 9.6 South America - Market size and forecast 2023-2028
• 9.7 Middle East and Africa - Market size and forecast 2023-2028
• 9.8 US - Market size and forecast 2023-2028
• 9.9 China - Market size and forecast 2023-2028
• 9.10 Germany - Market size and forecast 2023-2028
• 9.11 UK - Market size and forecast 2023-2028
• 9.12 Japan - Market size and forecast 2023-2028
• 9.13 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Advanced Medical Solutions Group Plc
• 12.4 BASF SE
• 12.5 Berkeley Advanced Biomaterials
• 12.6 CAM Bioceramics BV
• 12.7 CoorsTek Inc.
• 12.8 Corbion nv
• 12.9 Covestro AG
• 12.10 Dentsply Sirona Inc.
• 12.11 Evonik Industries AG
• 12.12 Honeywell International Inc.
• 12.13 Koninklijke DSM NV
• 12.14 Regenity Biosciences
• 12.15 Stryker Corp.
• 12.16 Victrex Plc
• 12.17 Zimmer Biomet Holdings Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations